Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica NvfiledCriticalJanssen Pharmaceutica Nv
Publication of UY30152A1publicationCriticalpatent/UY30152A1/en
Pharmaceuticals Containing Other Organic And Inorganic Compounds
(AREA)
Abstract
La presente invención consiste en un método para el tratamiento de la depresión que comprende administrar a un sujeto que la necesita, una cantidad terapéuticamente eficaz de uno o más nuevos derivados benzo-heteroaril sulfamida de fnrmula (I) tal como los definidos aquí. La presente invención está dirigida a un mctodo para el tratamiento de la depresión que incluye mono-terapia y alternativamente, co-terapia con por lo menos un antidepresivo.The present invention consists of a method for the treatment of depression which comprises administering to a subject in need thereof, a therapeutically effective amount of one or more new benzo-heteroaryl sulfonamide derivatives of formula (I) as defined herein. The present invention is directed to a method for the treatment of depression that includes mono-therapy and alternatively, co-therapy with at least one antidepressant.
UY30152A2006-02-152007-02-14
USE OF BENZO-HETEROARIL SULFAMIDA DERIVATIVES FOR THE TREATMENT OF DEPRESSION
UY30152A1
(en)
Use of specific sgc stimulating and / or activating compounds; pharmaceutical formulation comprising said compounds; kit comprising the compounds, and use for the prevention and / or treatment of systematic sclerosis.
COMBINATION OF A NUCLEOSIDE POLYMERASE INHIBITOR WITH A MACROCYCLY PROTEASE INHIBITOR AND ITS USE IN THE TREATMENT OF HEPATITIS C, HEPATIC FIBROSIS AND ALTERED HEPATIC FUNCTION
Macrocyclic aminoindole derived compounds; pharmaceutical composition comprising said compound; and use of the compound for the treatment of hepatitis c.
Compounds derived from n-cyclohexyl-2-phenoxynicotinamide; pharmaceutical composition comprising them; pharmaceutical combination comprising them; and its use to treat a disease mediated by pde4.
Method for treating or preventing cancer, which comprises administering a synergistic pharmaceutical combination of: a) (s) -n- (3,4-difluoro-2- (2-fluoro-4-iodophenylamino) -6-methoxyphenyl) -1 - (2,3-dihydroxypropyl) cyclopropan-1-sulfonamide and b) 3- (6,7-bis (2-methoxyethoxy) quinazolin-4-ylamino) benzonitrile; pharmaceutical composition; and pharmaceutical kit.
Compounds derived from substituted 1H-pyrazoles, inhibitors of kinase-catalyzed reactions; its preparation procedure; pharmaceutical composition; intermediate compounds; use of the main compounds, useful in the treatment of cancer.